There are 511 resources available
320P - Effect of clinical trial eligibility criteria on patient selection for advanced biliary tract cancers
Presenter: Charlotte Walmsley
Session: Poster Display session
Resources:
Abstract
321P - The co-location of MARCO+ tumor-associated macrophages and CTSE+ tumor cells determined the poor prognosis in intrahepatic cholangiocarcinoma
Presenter: Guangyu Fan
Session: Poster Display session
Resources:
Abstract
322P - Exploring the role of canonical WNT signaling in gallbladder cancer progression and therapeutic implications of XAV939
Presenter: Akanksha kashyap
Session: Poster Display session
Resources:
Abstract
323P - NALIRIFOX versus nab-paclitaxel and gemcitabine (Gem+NabP) in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Subgroup analysis of patients aged 65 years or older in NAPOLI 3
Presenter: Teresa Macarulla Mercade
Session: Poster Display session
Resources:
Abstract
324P - Effect of NALIRIFOX in Asian patients (pts) with treatment-naive metastatic pancreatic adenocarcinoma (mPAC): Results from the NAPOLI 3 trial
Presenter: Davide Melisi
Session: Poster Display session
Resources:
Abstract
325P - Losartan plus mFOLFIRINOX versus mFOLFIRINOX in advanced pancreatic adenocarcinomas: A two-arm open label prospective parallel design randomized superiority clinical trial (AFPAC)
Presenter: Vikas Ostwal
Session: Poster Display session
Resources:
Abstract
326P - NeoPancONE: Feasibility of completing a neoadjuvant multicentre phase II study in resectable pancreatic ductal adenocarcinoma (r-PDAC), treated with modified FOLFIRINOX (mFFX)
Presenter: Ronan Mclaughlin
Session: Poster Display session
Resources:
Abstract
327P - A strategic combination of induction FOLFIRINOX and chemoradiation in locally advanced pancreatic cancer: A phase II trial
Presenter: Michele Fiore
Session: Poster Display session
Resources:
Abstract
328P - Trifluridine/tipiracil (FTD/TPI) in patients with fluoropyrimidine refractory advanced pancreatic adenocarcinoma: A single-arm phase II trial
Presenter: Chi Leung Chiang
Session: Poster Display session
Resources:
Abstract
329P - Nadunolimab, a first-in-class monoclonal antibody against IL1RAP, in advanced pancreatic cancer
Presenter: Eric Van Cutsem
Session: Poster Display session
Resources:
Abstract